Search - tctmd.com

Displaying 281 - 300 of 372

Sort: Relevancy | Date

Presentation TCT 2015

TCT 57: A Cost Analysis of Bleed Complications From 2 Stroke Prevention Strategies in Nonvalvular Atrial Fibrillation: Left Atrial Appendage Closure Versus Warfarin

Presenter: Jacqueline Saw, Steven J. Yakubov, Matthew J. Price

October 13, 2015

Presentation TCT 2015

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz

October 13, 2015

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

Speakers Consider the Efficacy of Hemodynamic Support for Cardiogenic Shock After Acute MI

October 12, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

News Conference News TCT 2015

SYNTAX Analysis: MI-Related Deaths More Common With PCI vs. CABG

October 11, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

News Conference News TCT 2014

Meta-analyses Explore Cerebrovascular Protection, TIA and Stroke Risk with Carotid Stenting

September 22, 2014

News Conference News TCT 2014

Real-World Data Show Correlation Between Post-PCI Angina, Resource Utilization

September 18, 2014

Presentation TCT 2014

Neurological Complications of TEVAR: Prevention and Management

Presenter: Wilson Y. Szeto, Rodney White, Frank J. Criado, Alan B. Lumsden

September 16, 2014

Presentation TCT 2014

Flash Debate: Statins for Contrast Nephropathy Prevention Ready for Prime Time? Con!

Presenter: Antonio L. Bartorelli, Somjot S. Brar, Roxana Mehran, Richard Solomon

September 16, 2014

News Conference News TCT 2014

Experts Consider Role of Statins in Prevention of Contrast-Induced Nephropathy

September 16, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Presentation TCT 2014

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Jonathan L. Halperin

September 15, 2014

Advertisement

TCT 57: A Cost Analysis of Bleed Complications From 2 Stroke Prevention Strategies in Nonvalvular Atrial Fibrillation: Left Atrial Appendage Closure Versus Warfarin

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Discussion Highlights Merits, Limitations of Small Trials

Speakers Consider the Efficacy of Hemodynamic Support for Cardiogenic Shock After Acute MI

DAPT Study Subanalysis Focuses on EES Subgroup

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

SYNTAX Analysis: MI-Related Deaths More Common With PCI vs. CABG

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Meta-analyses Explore Cerebrovascular Protection, TIA and Stroke Risk with Carotid Stenting

Real-World Data Show Correlation Between Post-PCI Angina, Resource Utilization

Neurological Complications of TEVAR: Prevention and Management

Flash Debate: Statins for Contrast Nephropathy Prevention Ready for Prime Time? Con!

Experts Consider Role of Statins in Prevention of Contrast-Induced Nephropathy

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content